Dupixent

Market Access

Sanofi's Dupixent gets FDA nod for chronic hives indication

Dupixent's seventh indication is chronic hives, where a new treatment hasn't been approved since Novartis's Xolair in 2014

News

Can Dupixent plug treatment gap in bullous pemphigoid?

The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.

News

Sanofi's Dupixent scores double COPD win in US, China

Originally anticipated in June, the FDA action stands to make Sanofi and Regeneron's biologic blockbuster even bigger.

News

Dupixent delivers in two skin disease trials

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications f

News

GSK says Nucala hits the target in new COPD trial

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<

News

Galderma's chief executive Flemming Ørnskov

Galderma gets FDA nod for prurigo nodularis therapy

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales.

Sanofi's Dupixent gets FDA nod for chronic hives indication

Can Dupixent plug treatment gap in bullous pemphigoid?

Sanofi's Dupixent scores double COPD win in US, China

Dupixent delivers in two skin disease trials

GSK says Nucala hits the target in new COPD trial

Galderma gets FDA nod for prurigo nodularis therapy

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Dupixent

Editor's Picks